Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 15/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29764486 | 1.00 | FBP1 (0.64) | FBP1APEX1TSHRNPC1MAPT | |
| SCHEMBL1653140 | 0.82 | FBP1 (0.49) | FBP1NPC1MAPTL3MBTL1KDM4E | |
| SCHEMBL28463825 | 0.82 | FBP1 (0.63) | FBP1APEX1KDM4E | |
| SCHEMBL1850124 | 0.81 | KDM4E (0.53) | MAPTKDM4EHPGD | |
| SCHEMBL28461402 | 0.79 | FBP1 (1.00) | FBP1APEX1 | |
| SCHEMBL28471058 | 0.79 | FBP1 (1.00) | FBP1NPC1MAPTMAPK1 | |
| SCHEMBL28465593 | 0.78 | FBP1 (0.72) | FBP1 | |
| SCHEMBL28467675 | 0.78 | FBP1 (0.85) | FBP1 | |
| SCHEMBL28465619 | 0.78 | FBP1 (0.73) | FBP1 | |
| SCHEMBL28465141 | 0.77 | FBP1 (0.55) | FBP1APEX1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2022169755-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| US-7834049-B2 | Sulfonamide compound for treating arteriosclerosis, psoriasis, colon cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | WAKABAYASHI TOSHIAKI | 2010-10-21 | — | — | US | disclosed |
| EP-1258252-B1 | INTEGRIN EXPRESSION INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2010-04-21 | — | — | EP | disclosed |
| CN-100356979-C | Integrin expression inhibitors | EISAI CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-20050176712-A1 | Integrin expression inhibitor | EISAI CO., LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20040018192-A1 | Integrin expression inhibitors | EISAI CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| US-6673787-B2 | PYRIMIDINESULFONAMIDE CONTAINING INDOLE COMPOUNDS USED AS ANTIANGIOGENIC AND ANTITUMOR AGENTS | EISAI CO., LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| US-6638964-B2 | Pyridinesulfonamide containing indole compounds used as antiangiogenic and antitumor agents | EISAI CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| CN-1396833-A | Integrin expression inhibitors | EISAI CO LTD (JP) | 2003-02-12 | — | — | CN | disclosed |
| EP-1258252-A1 | INTEGRIN EXPRESSION INHIBITORS | Eisai Co., Ltd. (JP) | 2002-11-20 | — | — | EP | disclosed |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | EISAI CO., LTD. | 2002-09-12 | — | — | US | disclosed |
| EP-1074542-A1 | SULFONAMIDE-CONTAINING INDOLE COMPOUNDS | Eisai Co., Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176712-A1 | Integrin expression inhibitor | ITGB5, ITGB1, ITGB2 | FBP1 3805/4885APEX1 4311/4885TSHR 611/4885 |
| US-20020128480-A1 | Sulfonamide-containing indole compounds | IDO1, HCCS, VEGFA | FBP1 2343/4885APEX1 3426/4885TSHR 1158/4885 |
| US-20240190821-A1 | SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF | PACSIN2, TPX2, PRSS12 | FBP1 2679/4885APEX1 4176/4885TSHR 3294/4885 |
| US-20100267754-A1 | INTEGRIN EXPRESSION INHIBITOR | ITGB5, ITGB1, ITGB2 | FBP1 3805/4885APEX1 4311/4885TSHR 611/4885 |
| US-20040018192-A1 | Integrin expression inhibitors | ITGB1, ITGB4, ITGB5 | FBP1 3525/4885APEX1 4210/4885TSHR 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.